Brookline Capital Markets Starts (BIOX) at Buy

Brookline Capital Markets analyst Sally Yanchus initiates coverage on (NYSE: BIOX) with a Buy rating and a price target of $13.00.

Analyst says: " The launch of EcoSoy in the US and China could transform BIOX, potentially more than doubling the current annual revenue base of $180m by 2023. The global market for agricultural biological crop offerings including seeds is estimated to be $56B and growing."

For an analyst ratings summary and ratings history on click here. For more ratings news on click here.

Shares of closed at $4.95 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'